SCHEMBL24609142

SCHEMBL24609142

CCOC(=O)N1CCCN(C2CCC(NC)(c3ccccc3C(F)(F)F)CC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.48
SLC6A4 P31645 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
POLB P06746 1/20 0.43
CHRM1 P11229 3/20 0.42
MAPK1 P28482 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
KCNH2 Q12809 1/20 0.41
GRIN2B Q13224 1/20 0.41
ALOX12 P18054 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM3 P20309 1/20 0.40
PDK2 Q15119 1/20 0.40
TRPV6 Q9H1D0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20066016 0.85 GAA (0.45) GAASLC6A4HRH3L3MBTL1POLB
SCHEMBL20073973 0.84 POLB (0.48) GAAHRH3L3MBTL1POLBCHRM1
SCHEMBL24609048 0.81 MEN1 (0.49) L3MBTL1POLBCHRM1MAPK1MEN1
SCHEMBL24609204 0.78 SMN1; SMN2 (0.52) GAASLC6A4HRH3POLBCHRM1
SCHEMBL24609120 0.78 MAPK1 (0.46) GAAHRH3POLBCHRM1MAPK1
SCHEMBL24609202 0.77 CHRM2 (0.54) CHRM1MAPK1MEN1KMT2ACHRM2
SCHEMBL24609124 0.75 NOS2 (0.51) GAAPOLBCHRM1MAPK1MEN1
SCHEMBL24609151 0.74 MAPK1 (0.42) GAAHRH3CHRM1MAPK1KCNH2
SCHEMBL23799245 0.74 POLB (0.48) GAAHRH3L3MBTL1POLBCHRM1
SCHEMBL20066046 0.74 OPRM1 (0.46) GAAHRH3L3MBTL1POLBCHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834407-B2 Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2023-12-05 US disclosed
US-20220213034-A1 SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2022-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213034-A1 SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM4 GAA 3017/4885SLC6A4 1365/4885HRH3 59/4885
US-11834407-B2 Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists CHRM1, CHRM2, CHRM4 GAA 3017/4885SLC6A4 1365/4885HRH3 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.